Skip to main content
. 2018 Feb 8;7(5):e1426517. doi: 10.1080/2162402X.2018.1426517

Figure 3.

Figure 3.

Anti-CD200 antibody effectively targets MCC tumor cells in vivo. (A) schematic of experiment illustrating the intravenous infusion of human IgG4 anti-CD200 antibody followed by 6-hour washout period. The MCC xenograft tumor was then collected and tissues were stained with an anti-human-IgG secondary antibody. (B) Anti-CD200 antibody was not detected in overlying mouse epidermis, (C) but heavily deposited on viable MCC tumor cells.